Estados financieros detallados de Aclaris Therapeutics, Inc. (ACRS): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Aclaris Therapeutics, Inc. registró ingresos de $7.8M en el último ejercicio fiscal, con un CAGR de 5 años del 3.8%.
Márgenes de los últimos 12 meses: margen bruto 95.6%, margen operativo -10.5%, margen neto -9.2%.
Al precio actual de $5.32, ACRS presenta beneficios negativos (P/E no significativo) y un ROE del -61.65%. La capitalización bursátil es de $743M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | $1.7M | $10.1M | $4.2M | $6.5M | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M |
| Coste de Ventas | $120000 | $1.2M | $6.8M | $4.1M | $5.1M | $4.7M | $12.0M | $18.1M | $2.8M | $2.1M |
| Beneficio Bruto | -$120000 | $476000 | $3.2M | $172000 | $1.3M | $2.0M | $17.8M | $13.2M | $15.9M | $5.7M |
| I+D | $33.5M | $39.8M | $63.0M | $64.9M | $29.3M | $43.8M | $77.8M | $98.4M | $33.6M | $52.6M |
| Generales y Administrativos | $15.1M | $33.1M | $75.6M | $27.8M | $20.5M | $23.6M | $25.1M | $31.1M | $22.2M | $22.0M |
| Gastos Operativos | $48.6M | $72.9M | $138.7M | $92.7M | $52.3M | $91.8M | $107.6M | $110.5M | $157.9M | $82.1M |
| Beneficio Operativo | -$48.6M | -$72.4M | -$135.4M | -$111.1M | -$50.9M | -$89.7M | -$89.9M | -$97.4M | -$141.9M | -$76.4M |
| EBITDA | -$48.6M | -$53.5M | -$80.8M | -$90.2M | -$47.2M | -$64.5M | -$84.4M | -$115.5M | -$51.7M | -$64.5M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$48.1M | -$70.4M | -$132.7M | -$113.5M | -$51.3M | -$90.9M | -$86.9M | -$88.8M | -$132.1M | -$64.9M |
| Impuestos | -$120000 | -$1.8M | $2.7M | 0 | -$182000 | 0 | 0 | -$367000 | 0 | 0 |
| Beneficio Neto | -$48.1M | -$68.5M | -$132.7M | -$161.4M | -$51.0M | -$90.9M | -$86.9M | -$88.5M | -$132.1M | -$64.9M |
| BPA | $-2.25 | $-2.44 | $-4.03 | $-3.46 | $-1.20 | $-1.60 | $-1.33 | $-1.27 | $-1.71 | $-0.53 |
| BPA Diluido | $-2.25 | $-2.44 | $-4.03 | $-3.46 | $-1.20 | $-1.60 | $-1.33 | $-1.27 | $-1.71 | $-0.53 |
| Acciones en Circulación (Diluidas) | $21.4M | $28.1M | $32.9M | $41.3M | $42.5M | $56.7M | $65.2M | $69.8M | $77.3M | $122.7M |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $30.2M | $208.9M | $57.0M | $34.2M | $22.1M | $27.3M | $45.3M | $39.9M | $24.6M | $20.0M |
| Inversiones a Corto | $107.1M | 0 | $111.0M | $39.1M | $32.1M | $164.1M | $172.3M | $79.2M | $89.0M | $70.8M |
| Cuentas por Cobrar | 0 | $481000 | $563000 | $704000 | $772000 | $623000 | $484000 | $298000 | $318000 | $5.6M |
| Inventario | 0 | -$6.4M | $791000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $174.1M | $208.9M | $179.5M | $83.8M | $57.5M | $205.0M | $231.6M | $128.9M | $126.0M | $151.4M |
| Inmovilizado Material | $481000 | $2.2M | $4.3M | $2.5M | $1.7M | $1.3M | $1.1M | $1.6M | $1.0M | 0 |
| Fondo de Comercio | 0 | $18.5M | $18.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | $7.3M | $73.0M | $7.2M | $7.1M | $7.0M | $7.0M | $269000 | 0 | 0 |
| Activos Totales | $176.1M | $243.5M | $275.6M | $98.3M | $70.8M | $251.2M | $254.6M | $197.4M | $220.3M | $160.5M |
| Cuentas por Pagar | $2.8M | $7.8M | $11.7M | $9.9M | $5.3M | $10.0M | $10.4M | $8.9M | $4.7M | $13.2M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $551000 |
| Pasivos Corrientes | $6.2M | $12.8M | $27.3M | $22.4M | $14.9M | $22.9M | $21.9M | $31.0M | $31.6M | $28.6M |
| Deuda a Largo | 0 | 0 | $29.9M | 0 | $10.7M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $6.6M | $18.2M | $60.4M | $28.4M | $33.1M | $53.9M | $57.0M | $40.2M | $64.8M | $57.4M |
| Reservas | -$90.9M | -$159.4M | -$292.2M | -$453.5M | -$504.5M | -$595.4M | -$682.3M | -$770.8M | -$902.9M | -$967.8M |
| Patrimonio Neto | $169.5M | $225.3M | $215.1M | $69.9M | $37.6M | $197.3M | $197.6M | $157.2M | $155.6M | $103.1M |
| Deuda Total | 0 | $142000 | $30.5M | $637000 | $11.3M | $693000 | $684000 | $426000 | 0 | $2.1M |
| Deuda Neta | -$174.1M | -$208.7M | -$137.5M | -$72.6M | -$42.9M | -$190.7M | -$216.9M | -$118.7M | -$113.6M | -$88.6M |
| Capital Circulante | $167.9M | $196.1M | $152.2M | $61.4M | $42.6M | $182.1M | $209.6M | $97.9M | $94.4M | $122.7M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$48.1M | -$68.5M | -$132.7M | -$113.5M | -$51.0M | -$90.9M | -$86.9M | -$88.5M | -$132.1M | -$64.9M |
| Amortizaciones | $120000 | $402000 | $1.9M | $1.6M | $1.3M | $923000 | $797000 | $863000 | $807000 | $454000 |
| Compensación en Acciones | $6.1M | $14.4M | $20.1M | 0 | $11.2M | $14.1M | $15.0M | $20.5M | $10.9M | $12.4M |
| Cambio en Capital Circulante | $4.3M | $865000 | $9.4M | -$2.7M | -$2.4M | -$1.3M | -$1.2M | $9.4M | $10.9M | $2.7M |
| Flujo de Caja Operativo | -$34.6M | -$54.7M | -$100.8M | -$96.4M | -$38.6M | -$52.1M | -$67.6M | -$78.3M | -$20.1M | -$47.1M |
| Inversiones (CapEx) | -$232000 | -$1.2M | -$1.4M | -$1.6M | -$453000 | -$308000 | -$605000 | -$1.3M | -$121000 | -$111000 |
| Adquisiciones | 0 | -$9.6M | -$67.1M | 0 | 0 | $167.3M | -$13.2M | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$446000 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$34.8M | -$55.9M | -$102.2M | -$98.1M | -$39.1M | -$52.4M | -$68.2M | -$79.6M | -$20.2M | -$47.1M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | +499.6% | -58.1% | +53.3% | +4.3% | +340.1% | +5.0% | -40.1% | -58.2% | ||
| Crecimiento Beneficio Neto (anual) | -42.5% | -93.7% | -21.6% | +68.4% | -78.1% | +4.4% | -1.8% | -49.3% | +50.8% | |
| Crecimiento BPA (anual) | -8.4% | -65.2% | +14.1% | +65.3% | -33.3% | +16.9% | +4.5% | -34.6% | +69.0% | |
| Cambio en Acciones (anual) | +31.2% | +17.1% | +25.6% | +2.9% | +33.4% | +15.0% | +7.0% | +10.7% | +58.7% | |
| Crecimiento FCF (anual) | -60.5% | -82.8% | +4.0% | +60.1% | -34.2% | -30.0% | -16.8% | +74.6% | -133.3% | |
| Margen Bruto | 28.3% | 32.1% | 4.1% | 20.8% | 30.3% | 59.8% | 42.1% | 85.1% | 73.3% | |
| Margen Operativo | -4303.2% | -1341.9% | -2627.3% | -785.4% | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% | |
| Margen EBITDA | -3176.1% | -800.5% | -2134.7% | -728.1% | -953.4% | -283.5% | -369.5% | -276.3% | -823.8% | |
| Margen Neto | -4071.5% | -1315.4% | -3817.2% | -787.0% | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% | |
| Margen FCF | -3321.3% | -1012.5% | -2319.8% | -603.0% | -775.7% | -229.1% | -254.8% | -107.9% | -602.0% | |
| Tasa Impositiva Efectiva | 0.2% | 2.6% | -2.0% | -0.0% | 0.4% | -0.0% | -0.0% | 0.4% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-1.63 | $-1.99 | $-3.10 | $-2.37 | $-0.92 | $-0.92 | $-1.05 | $-1.14 | $-0.26 | $-0.38 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $21.4M | $28.1M | $32.9M | $41.3M | $42.5M | $56.7M | $65.2M | $69.8M | $77.3M | $122.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -61.65% |
| Rentabilidad sobre capital invertido | -56.99% |
| Rentabilidad sobre activos | -42.15% |
| Margen bruto | 95.61% |
| Margen operativo | -1050.16% |
| Margen neto | -921.50% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 3.46 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -5.19 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -12.06 | -10.11 | -1.83 | -0.55 | -5.39 | -9.09 | -11.84 | -0.83 | -1.45 | -5.68 |
| P/VC | 3.43 | 3.08 | 1.13 | 1.12 | 7.31 | 4.18 | 5.20 | 0.47 | 1.23 | 3.58 |
| P/V | 0.00 | 411.77 | 24.10 | 18.48 | 42.46 | 122.00 | 34.52 | 2.35 | 10.24 | 47.18 |
| Margen Bruto | 0.0% | 28.3% | 32.1% | 4.1% | 20.8% | 30.3% | 59.8% | 42.1% | 85.1% | 73.3% |
| Margen Operativo | 0.0% | -4303.2% | -1341.9% | -2627.3% | -785.4% | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% |
| Margen Neto | 0.0% | -4071.5% | -1315.4% | -3817.2% | -787.0% | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% |
Empresas relacionadas: ALLO · BIOA · CABA · EDIT · MASS · MDXH · NEO
Explorar sector: Healthcare · Biotechnology
Más secciones de ACRS: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones